About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Ibai Los Arcos Bertiz Collaborators: M Teresa Martin Gomez, Yolanda Villena Ortiz, Javier Gomis Rodriguez, Joan Gavaldà Santapau, Judith Sacanell Lacasa, Marta Zapata Ortega, Leire Sanchez Corujo Funding agency: Instituto de Salud Carlos III Funding: 37500 Reference: PI23/01467 Duration: 01/01/2024 - 31/12/2026
IP: Joaquin Seras Franzoso Collaborators: Diana Fernandes de Rafael Funding agency: Asociación Cáncer de Páncreas Funding: 50000 Reference: ACANPAN/PROJECTES/2023/SERAS Duration: 05/12/2023 - 04/12/2025
IP: Francesc Moreso Mateos Collaborators: Gema Ariceta Iraola, Joan López Hellin Funding agency: Instituto de Salud Carlos III Funding: 42900 Reference: PMP22/00119 Duration: 01/01/2023 - 31/12/2025
IP: Concepció Jacobs Cachá Collaborators: Manuel Hernández González, Natalia Ramos Terrades, Joana Sellarés Roig, Carmen Llorens Cebriá, Janire Perurena Prieto Funding agency: Sociedad Española de NefrologÃa (S.E.N.) Funding: 24000 Reference: SENEFRO/PROJECTES/2023/JACOBS Duration: 23/12/2023 - 22/12/2025
PMID: 37570527 Journal: Nanomaterials Year: 2023 Reference: Nanomaterials (Basel). 2023 Jul 29;13(15):2208. doi: 10.3390/nano13152208. Impact factor: Publication type: Paper in international publication Authors: Abasolo, Ibane; Bastus, Neus G; Boullosa, Ana Maria; Camara, Juan Antonio; Casals, Eudald; Garcia, Ana; Gusta, Muriel F; Mondragon, Laura; Puntes, Victor; Schwartz, Simo Jr et al. DOI: 10.3390/nano13152208
PMID: 37593971 Journal: TRANSFUSION Year: 2023 Reference: Transfusion. 2023 Aug 18. doi: 10.1111/trf.17498. Impact factor: Publication type: Letter or abstract Authors: Alvarez Arguelles, Marta Elena; Garcia-Gala, Jose Maria; Mata, Pablo; Munoz, Maria Del Carmen; Ojea, Ana Maria; Quer Sivila, Josep; Rando Segura, Ariadna; Rodriguez, Mercedes; Rodriguez-Frias, Francisco; Seco, Carolina et al. DOI: 10.1111/trf.17498
PMID: 37626646 Journal: Biomedicines Year: 2023 Reference: Biomedicines. 2023 Jul 30;11(8):2149. doi: 10.3390/biomedicines11082149. Impact factor: Publication type: Paper in international publication Authors: Baldira, Jaume; Chiscano, Luis; Comas, Inma; Cortes, Alejandro; Ferrer, Ricard; Ferrer-Costa, Roser; Gonzalez-Lopez, Juan Jose; Larrosa, Maria Nieves; Ruiz-Rodriguez, Juan Carlos; Ruiz-Sanmartin, Adolfo et al. DOI: 10.3390/biomedicines11082149
PMID: 37696147 Journal: European Journal of Obstetrics & Gynecology and Reproductive Biology Year: 2023 Reference: Eur J Obstet Gynecol Reprod Biol. 2023 Aug 23;289:203-207. doi: 10.1016/j.ejogrb.2023.08.376. Impact factor: Publication type: Paper in international publication Authors: Beneitez, D; Beneitez, D; Bergamo, S; Carbonell, M; Carbonell, M; Carreras, E; Carreras, E; Castillo, F; Castillo, F; Cespedes, M C et al. DOI: 10.1016/j.ejogrb.2023.08.376
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.
Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.
